Accessible Search Form           Advanced Search

Skip left side navigation and go to content

NHLBI SBIR/STTR

Omnibus Grant Solicitations (for investigator-initiated applications)

Standard receipt dates apply
April 5, August 5, December 5 for non-HIV related applications
May 7, September 7, January 7 for AIDS and AIDS-related applications

The NHLBI accepts investigator-initiated Phase I and Phase II grant applications that are relevant to the NHLBI mission through the Department of Health and Human Services Omnibus SBIR and STTR Grant Solicitations.

New this year is the opportunity to bypass Phase I and apply directly to Phase II if you have preliminary data equivalent to what would normally be done in a Phase I grant (proof-of-concept). Read the Direct to Phase II funding opportunity announcement.

While the NHLBI has identified some areas of unmet needs of particular interest (please see below), the NHLBI also encourages mission-aligned applications for innovative technologies outside these targeted areas.

For important information about NHLBI's participation in the SBIR/STTR programs, please see the Program Descriptions and Research Topics image of PDF icon (1 MB). This document also contains information on submitting budgets exceeding the normal budget guidelines. See Appendix A image of PDF icon (1 MB) for more information.

Unmet Needs of Particular Interest for Fiscal Year 2015

Topics are listed here to inform potential applicants about areas of particular interest to the NHLBI.

Applications submitted in response to the Omnibus Grant Solicitations are not limited to the research and development areas described below.

Instructions for submitting applications in response to the following areas:

  • At the beginning of the title, please include the following four characters: HLS- (Important: according to the NIH's SF424 (R&R) Application Guideimage of PDF icon (2.6 MB), NIH limits title character length to 81 characters including the spaces between words and punctuation. Titles in excess of 81 characters will be truncated).
  • In the first sentence of the abstract, please include the code shown in the last column of the table below. This coding is for internal NHLBI tracking purposes only.


Topic Code
Animal and Cellular Models:
  • for rare non-malignant and  pre-malignant (MDS & MPD) hematologic disorders
  • for complications associated with thrombosis
  • for transfusion of blood products or cell-based  therapies
HLS15-01
Research tools:  Imaging, reagents, assays including microassays, microfluidics, bioinformatics and nanotechnology for investigations of blood diseases, transfusion and cellular therapies  HLS15-02
Diagnostics: devices, biomarkers, imaging, and assays for non-malignant blood disorders  HLS15-03
Therapeutics:  drugs, blood product and cellular therapies, and gene therapy for non-malignant blood disorders  HLS15-04
E-medicine Apps for patients and medical professionals to improve the management of and reduce the impact of non-malignant blood diseases  HLS15-05
Development of molecular imaging reagents/techniques and nanotechnology-based drug delivery systems which would detect and then allow for specific targeting of lung diseases, such as plexiform lesions in PAH and/or microvascular loci susceptible to rarefaction/pruning in obstructive airway diseases like emphysema, or fibrotic triggers in IPF. HLS15-06
Development of reagents and methods to identify and isolate stem/progenitor cells, and direct differentiation to specific functional organ units. These reagents may include antibodies for stem/progenitor cell detection and sorting, biomaterials for optimizing the microniches of stem/progenitor cells, as well as methods for 3-D regeneration of tissue. HLS15-07
Development and validation of techniques(or algorithms) to study the microbiome in situ, including, but not limited to:
  • Sampling the microbiome of different lung or gut segments while minimizing contamination from other locations.
  • Development of an analytical system to study the metabolic products of the lung and gut microbiome from breath condensate
HLS15-08
Characterization and in vivo / in vitro applications of miRNA panels that target lung-resident mesenchymal or fibroblast cells and promote directly or indirectly lung repair/regeneration HLS15-09
Development of high throughput methods to apply microfluidics technology in discovery of molecular profiles (DNAs, RNAs, proteins, or metabolites) in a large number of sputum or exhaled breath condensate samples collected from lung disease patients.   HLS15-10
Develop a biocompatible fluid sealant and associated transcatheter technique to permanently seal paravalvular leaks resulting from transcatheter cardiac valve replacement HLS15-11
Develop smart phone apps and other communication tools to increase accessibility and evaluation of the latest educational materials and trial research on cardiovascular, nutritional and physical activity information for medical professionals and patients (English and non-English speakers) HLS15-12
Innovative Point-of-Care technologies to guide diagnostic, monitoring or therapeutic efforts in clinical studies of cardiovascular, lung, and blood diseases and disorders HLS15-13
Improved diagnostics, monitoring technologies and therapeutics for arterial stiffness and peripheral vascular diseases (e.g., aortic aneurysms, venous and lymphatic disorders, and vascular malformations) HLS15-14
Develop a technology that enables immediate, user-friendly measures of average daily sodium intake. These technologies would replace the current standard of 24-hour urine collection HLS15-15
Develop a fast, easy-to-use, clinical device for measuring increases in arterial stiffness (as an early predictor of high blood pressure), or diminished blood flow in the lower extremities (as a indicator of propensity towards peripheral artery disease) HLS15-16

For questions, contact us.

Last Updated April 2014

Twitter iconTwitterimage of external icon Facebook iconFacebookimage of external icon YouTube iconYouTubeimage of external icon Google+ iconGoogle+image of external icon